Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem vs Piperacillin/Tazobactam in Burn Sepsis
NCT07096310Phase 2Active, not recruiting
- Sponsor
- Ain Shams University
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of piperacillin + tazobactam in sepsis, sponsored by Ain Shams University. Started Jan 2024; status: active, not recruiting.
02
Drugs
piperacillin + tazobactam
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT07096310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096310.